Abbott achieved a favorable procedural outcome — broad discovery expansion was denied and the case is on track for summary judgment resolution within weeks. The company's denial of the plaintiffs' request to reopen discovery limits the scope of evidence plaintiffs can use, reducing settlement leverage. Monitor the supplemental briefing due May 19 and June 2, 2026 for the court's summary judgment ruling. A grant of summary judgment would remove the case entirely; a denial would set up trial and materially increase ABT's liability exposure.
Price Chart
Executive Summary
The court denied plaintiffs' motion for sanctions against Abbott and denied their request to reopen discovery in this infant formula product liability case. The court granted only limited post-discovery production of Abbott's written response to the FDA's 2022 Establishment Inspection Report and a brief supplemental briefing schedule on Abbott's pending summary judgment motion. The ruling is a modest procedural win for Abbott: the case remains alive but plaintiffs were denied the broad discovery expansion they sought, and the core summary judgment motion is still pending with near-term resolution likely.
Court Ruling Details
Key Facts
- Plaintiffs' motion for sanctions against Abbott was DENIED for failure to follow local court rules
- Plaintiffs' request to reopen discovery for six months was DENIED
- Court ordered Abbott to produce its written response to the FDA's 2022 EIR by May 5, 2026
- Abbott's summary judgment motion is stayed for supplemental briefing; decision still pending
- Case is a product liability suit alleging infant formula contamination with Cronobacter sakazakii, filed September 2023
- Dismissal of a parallel FCA lawsuit (Millard) was unsealed November 2025; plaintiffs' two-month delay in seeking to use it weighed against reopening discovery
- No damages awarded or estimated in this order — it is a procedural ruling on discovery and scheduling
Financial Impact
No financial award or estimate in this ruling. This is a procedural/interlocutory order — no damages determined. The case has no stated financial exposure figure in the document.
Risk Factors
- If summary judgment is denied, the case proceeds to trial with product liability allegations still pending
- FDA 2022 EIR production (ordered by May 5) could produce damaging documents
- Underlying Cronobacter contamination allegations could attract additional lawsuits or regulatory scrutiny even if this case is resolved favorably
- Historical performance on ABT reports shows very low win rate (11% T+20), suggesting market frequently prices these events inefficiently
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-332r7b1d-ABT |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 today | ANALYST-UPGRADE | $98.00 awaiting T+5 | awaiting T+5 | — | $95.39 (−2.67%) |
Sep 14, 2026 18d ago | Court Ruling | $103.09 $102.98 | ▼ −0.11% | ▼ −1.77% | $95.39 (−7.47%) |
Aug 11, 2026 7w ago | Court Ruling | $109.72 $112.68 | ▲ +2.70% | ▲ +3.10% | $95.39 (−13.06%) |
Aug 11, 2026 7w ago | Court Ruling | $109.72 $112.68 | ▲ +2.70% | ▲ +3.10% | $95.39 (−13.06%) |
Jul 31, 2026 9w ago | Institutional Cluster | $105.70 $107.81 | ▲ +2.00% | ▼ −1.51% | $95.39 (−9.76%) |
Jul 31, 2026 9w ago | Court Ruling | $105.70 $107.81 | ▲ +2.00% | ▼ −1.51% | $95.39 (−9.76%) |
Jul 24, 2026 10w ago | Court Ruling | $103.06 $105.61 | ▲ +2.47% | ▲ +2.10% | $95.39 (−7.44%) |
Jul 16, 2026 11w ago | 8-K | $98.83 $100.75 | ▲ +1.94% | ▲ +3.61% | $95.39 (−3.48%) |
Jul 14, 2026 11w ago | Court Ruling | $88.96 $101.66 | ▲ +14.28% | ▲ +15.57% | $95.39 (+7.23%) |
Jul 7, 2026 12w ago | Court Ruling | $95.84 $88.96 | ▼ −7.18% | ▼ −7.73% | $95.39 (−0.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access